

Postpartum Plasmapheresis Treatment in a Severe Liver Enzyme Disorder

✉ Mehmet Ferdi KINCI^a,
 ✉ İlknur YEŞİLÇINAR^b,
 ✉ Özge ŞEHİRLİ KINCI^c,
 ✉ Ramazan Erda PAY^a,
 ✉ Bora COŞKUN^a,
 ✉ Kazım Emre KARAŞAHİN^a

^aClinic of Obstetric and Gynecology,
 Gülhane Training and Research Hospital,
 Ankara, TURKEY

^bBatman University of Health School,
 Batman, TURKEY

^cClinic of Obstetric and Gynecology,
 Kızılcahamam State Hospital,
 Ankara, TURKEY

Received: 16.10.2018

Accepted: 05.11.2018

Available online: 15.01.2019

Correspondence:

Mehmet Ferdi KINCI
 Clinic of Obstetric and Gynecology,
 Gülhane Training and Research Hospital,
 Ankara, TURKEY
 drferdikinci@gmail.com

Keywords: HELLP syndrome;
 plasmapheresis

We read the article by Koyuncu et al. with interest and since we have had experience on the subject because of a long time follow up of a similar case, we wanted to present our opinion, also to contribute and underline some different points about Postpartum Plasmapheresis Treatment in HELLP syndrome.¹

A 28-year-old G1P1 was admitted to our clinic at 36 weeks of gestation. The blood pressure (BP) value was 141/90 mmHg, her platelet counts were 72*10. e3/mikroL, in the biochemical examination; AST: 273 U/L, ALT: 286 U/L, GGT: 74 U/L, LDH: 551 U/L, CK: 194 U/L, d-dimer: 3.34 mg/L and protein was 2 positive in spot urine, preeclampsia was diagnosed an emergency caesarean section was done (Table 1). Magnesium infusion and anti-hypertensive treatment were started. Plasmapheresis treatment was planned after the surgery due to 10-12 schistocytes were observed in all areas in the peripheral blood smear. 17 units of fresh frozen plasma (FFP) were used during plasmapheresis. During the follow-up period in the intensive care unit, platelet values started to increase from day 3, and AST, ALT, LDH, total bilirubin, urea and creatinine values started to return to normal on the 3rd day (Table 1). On the 5th day after the plasmapheresis treatment, patients all vital signs and laboratory values returned to normal and she was discharged.

Plasmapheresis treatment is an alternative treatment that can be used in HELLP syndrome. It is based on removal of antibodies, immune complexes and some toxins from plasma. Although the mechanism of action of plasmapheresis in HELLP syndrome is not fully known, it is stated that in patients with resistant HELLP syndrome and with organ failure, it increases platelet count and improves renal function.² Plasma exchange is estimated to eliminate aggregate and procoagulant factors discharged from endothelial cells and active platelets.² There are no definitive statements about the indications, time and frequency of plasmapheresis in the literature. When limited number of studies are examined, postpartum 24-

TABLE 1: Laboratory results.

	First Application	(6 th hour)	After Treatment			5 th day (Before Discharge)
Hb (g/dL)	11.5	10.4	9.1	9.4	10.4	12.3
Platelet count (10.e3/mikroL)	85	87	109	116	137	256
AST (IU)	273	169	115	35	37	42
ALT (IU)	286	206	163	45	36	54
Urea (mg/dL)	32	31	28	25	31	34
Creatinin (mg/dL)	0.88	0.88	0.84	0.86	0.82	0.86
PTZ (second)	10.7	11.3	-	12	-	-
aPTT (second)	33.4	35.4	-	31	-	-
d-dimer (mg/L)	3.34	-	-	-	3.53	3.53
Fibrinogen (mg/L)	326	-	-	-	277	134

72 hours, it has been suggested to patients with platelet values below $100 * 10$ e3/microL. However it is not clear when it should be terminated, it is stated in a study that when platelets start to rise and the platelet count is $100 * 10$.e3/microL it can be terminated.² We performed plasmapheresis at postpartum 12th hour. We did not need to recur because the platelet values increased above $100 * 10$ e3/microL at 30th hour of plasmapheresis.

The pathophysiology and treatment of preeclampsia and HELLP syndrome are highly controversial for obstetricians.³ Plasmapheresis, which is an alternative treatment modality in HELLP syndrome, needs multidisciplinary approach such as; anesthesiologist, obstetrician, hematologist, blood banking and many equipment requiring, therefore is a difficult process. However, it is an alternative and life-saving treatment modality for the treatment of HELLP syndrome if it is administered with the right timing in right selected cases.

Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest

No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions

Idea/Concept: Mehmet Ferdi Kinci, Özge Şehirli Kinci; **Design:** İlknur Yeşilçınar, Ramazan Erda Pay; **Control/Supervision:** Bora Çoşkun, Kazım Emre Karaşahin; **Data Collection and/or Processing:** Mehmet Ferdi Kinci, İlknur Yeşilçınar; **Analysis and/or Interpretation:** Özge Şehirli Kinci, Ramazan Erda Pay; **Literature Review:** Bora Çoşkun, Kazım Emre Karaşahin; **Writing the Article:** Mehmet Ferdi Kinci, Ramazan Erda Pay; **Critical Review:** İlknur Yeşilçınar, Kazım Emre Karaşahin; **References and Fundings:** Özge Şehirli Kinci, Bora Çoşkun; **Materials:** Mehmet Ferdi Kinci.

REFERENCES

1. Koyuncu K, Kan Ö, Yüce T, Taskin S, Soylemez F. Postpartum plasmapheresis treatment in a severe liver enzyme disorder. JCOG 2018;28(2):75-7.
2. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169(4):1000-6.
3. Gokdemir İE, Evliyaoglu Ö, Çoskun B. The role of ADAMTS genes in preeclampsia. Turk J Obstet Gynecol 2016;13(3):149-53.